Oncothyreon Announces Appointment of Steven P. James to Board of Directors
March 03 2015 - 8:01AM
Oncothyreon Inc. (Nasdaq:ONTY) today announced the appointment of
Steven P. James to its board of directors.
"We are pleased to welcome Steve, with his extensive experience
in the leadership of development stage biotechnology companies and
business development, to our board of directors," said Robert L.
Kirkman, M.D., President and Chief Executive Officer of
Oncothyreon.
Mr. James served as President and Chief Executive Officer of
Labrys Biologics, Inc., from December 2012 until its acquisition by
Teva Pharmaceuticals in July 2014. He was President and Chief
Executive Officer of KAI Pharmaceuticals, Inc., from October 2004
until its acquisition by Amgen in July 2012. He was Senior Vice
President, Commercial Operations, at Exelixis, Inc., from 2003
until 2004. Previously he held senior business roles at
Sunesis Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc. He
began his career in new product planning at Eli Lilly and
Company. Mr. James is also a member of the board of directors
of Ocera Therapeutics, Inc., and Chrono Therapeutics. Mr.
James earned a Bachelor of Arts degree in biology from Brown
University and a Masters in Management degree from the Kellogg
Graduate School of Management at Northwestern University.
"I am delighted to join Oncothyreon's board of directors at a
time of significant potential growth for the company," said Mr.
James. "The initial data for ONT-380 in HER2-positive breast
cancer are encouraging and supportive of its further
development. In addition, the protocell technology has the
potential to create both exciting new product candidates for
Oncothyreon and meaningful business development opportunities."
About Oncothyreon
Oncothyreon is a clinical-stage biopharmaceutical company
specializing in the development of innovative therapeutic products
for the treatment of cancer. Our goal is to discover, develop and
commercialize novel compounds that have the potential to improve
the lives and outcomes of cancer patients. Our current
clinical-stage product candidates include ONT-380, an orally active
and selective small molecule HER2 inhibitor, and ONT-10, a
therapeutic vaccine targeting MUC1. We are developing preclinical
product candidates in oncology, and potentially certain rare
diseases, using our protocell technology. For more information,
visit www.oncothyreon.com.
Additional Information
Additional information relating to Oncothyreon can be found on
EDGAR at www.sec.gov and on SEDAR at www.sedar.com.
CONTACT: Investor and Media Relations Contact:
Julie Rathbun
Rathbun Communications
206-769-9219
ir@oncothyreon.com
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Apr 2024 to May 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From May 2023 to May 2024